Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Predictive Oncology Inc (POAI)
NASDAQ:POAI
RESEARCH TOOLSreports
Holding POAI?
Track your performance easily
POAI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.55 - $3.76
Previous Close$0.69
Volume145.78K
Average Volume (3M)109.15K
Market Cap
$4.58M
Enterprise Value$1.95M
Total Cash (Recent Filing)$5.33M
Total Debt (Recent Filing)$2.70M
Price to Earnings (P/E)―
Beta3.26
Next Earnings
Apr 08, 2025EPS Estimate
-$0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.06
Shares Outstanding6,666,993
10 Day Avg. Volume100,148
30 Day Avg. Volume109,152
Standard Deviation0.23
R-Squared0.07
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)1.13
Price to Sales (P/S)2.82
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.02
Enterprise Value/Gross Profit1.70
Enterprise Value/Ebitda-0.14
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Predictive Oncology News
PremiumCompany Announcements
Predictive Oncology Inc. Reports Q3 2024 Earnings
Bulls Say, Bears Say
Bulls Say
AI And Biomarker IdentificationThe proprietary AI platform PEDAL has demonstrated the potential to identify biomarkers in cancer patients, making it an attractive licensing target.
Biobank And Data DifferentiationPredictive Oncology’s biobank of over 150,000 tumor samples across 137 subtypes of tumor and accompanying tumor-drug response data is a key differentiator of the PEDAL platform.
Drug Development EnhancementPEDAL has the potential to improve the drug development process in multiple ways: enable an early view of a drug’s therapeutic potential, support the development of targeted therapy for patients with specific biomarkers, and cut cost and increase clinical success rates of drug development.
Bears Say
Financial PerformancePredictive Oncology reported lower than expected revenue for 3Q24, indicating potential financial challenges.
Stock RatingThe rating on POAI has been downgraded to Neutral from Buy due to uncertainties regarding the company’s strategic plan and financial overhang.
Strategic ReviewThe company is undergoing a strategic review, which includes evaluating alternatives like a sale of the company or its assets, creating uncertainty.
---
Ownership Overview
1.69% Insiders
1.63% Mutual Funds
0.35% Other Institutional Investors
95.27% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
POAI FAQ
What was Predictive Oncology Inc’s price range in the past 12 months?
Predictive Oncology Inc lowest stock price was $0.55 and its highest was $3.76 in the past 12 months.
What is Predictive Oncology Inc’s market cap?
Currently, no data Available
When is Predictive Oncology Inc’s upcoming earnings report date?
Predictive Oncology Inc’s upcoming earnings report date is Apr 08, 2025 which is in 138 days.
How were Predictive Oncology Inc’s earnings last quarter?
Predictive Oncology Inc released its earnings results on Nov 13, 2024. The company reported -$0.48 earnings per share for the quarter, missing the consensus estimate of -$0.32 by -$0.16.
Is Predictive Oncology Inc overvalued?
According to Wall Street analysts Predictive Oncology Inc’s price is currently Overvalued.
Does Predictive Oncology Inc pay dividends?
Predictive Oncology Inc does not currently pay dividends.
What is Predictive Oncology Inc’s EPS estimate?
Predictive Oncology Inc’s EPS estimate is -$0.25.
How many shares outstanding does Predictive Oncology Inc have?
Predictive Oncology Inc has 6,666,993 shares outstanding.
What happened to Predictive Oncology Inc’s price movement after its last earnings report?
Predictive Oncology Inc reported an EPS of -$0.48 in its last earnings report, missing expectations of -$0.32. Following the earnings report the stock price went up 2.532%.
Which hedge fund is a major shareholder of Predictive Oncology Inc?
Currently, no hedge funds are holding shares in POAI
---
Predictive Oncology Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
POAI Sentiment 100%
Sector Average 73%
Sector Average 73%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 7.5%
Last 30 Days ▲ 7.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-78.35%
12-Months-Change
Fundamentals
Return on Equity
-193.25%
Trailing 12-Months
Asset Growth
-58.73%
Trailing 12-Months
Company Description
Predictive Oncology Inc
Predictive Oncology, Inc. engages in the manufacture and distribution of healthcare products, and provision of related services. The company offers STREAMWAY System, which is an automated system for the collection and disposal of infectious fluids from surgical and other medical procedures. It operates through the Medical Device and Consumable Products segments. The company was founded by Lawrence W. Gadbaw, Peter L. Morawetz, and Jeffrey K. Drogue on April 23, 2002 and is headquartered in Eagan, MN.
---
POAI Earnings Call
Q2 2024
0:00 / 0:00
---
POAI Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Advaxis
―
Cyclacel Pharmaceuticals
―
Brainstorm Cell Therapeutics
―
TRACON Pharmaceuticals
―
---